NRX Gets FDA Guidance, Support on Depression Treatmetnt Filing

 A Type B meeting with the FDA was held on January 11, 2023.

Minutes of the meeting are expected to be available in approximately 30 days.

"We appreciate the FDA's ongoing guidance and support under the Breakthrough Therapy Designation associated with NRX-101 as well the previously issued Special Protocol Agreement for the treatment of Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior.  Our quest is to develop the first medicine to treat patients with suicidal depression and aim to develop a new drug therapy for post-traumatic stress disorder (PTSD)", said Stephen Willard, chief executive officer of NRx Pharmaceuticals.  "We look forward to continued discussions addressing our mutual goal to treat bipolar depression and suicidality at a time when someone in the United States attempts suicide every 27 seconds."

https://finance.yahoo.com/news/nrx-pharmaceuticals-provides-progress-interactions-114700377.html